CannabisNewsBreaks Archive - Page 394 of 420

WednesdayNov 08, 2017 12:14 pm

CannabisNewsBreaks – Skinvisible, Inc. (SKVI) Develops Hemp-based Products with an Enhanced Delivery System

Skinvisible, Inc.’s (OTCQB: SKVI) proprietary topical drug delivery technology, Invisicare®, improves the delivery of pharmaceutical and medicinal compounds to and through the skin. The company develops hemp-based products and recently expanded its product line to the enter the cannabis-based topical product market. An article discussing this reads: “The patented polymer technology has been used in cosmeceutical, over-the-counter and pharmaceutical products for nearly two decades. On September 28, 2017, Skinvisible signed an exclusive agreement with Canopy Growth Corporation for the purpose of increasing its reach to Canada and establishing its position on the cannabis product markets. The definitive licensing agreement for…

WednesdayNov 08, 2017 11:47 am

CannabisNewsBreaks – PotNetwork Holding, Inc. (POTN) CEO Interviewed on Small Cap Spotlight Podcast

PotNetwork Holding, Inc. (OTC: POTN) this morning announced that Dr. Richard Goulding, its new chief executive officer, has been interviewed by Dave Donlin on the Small Cap Spotlight Podcast, which is featured exclusively on PublicWire.com. In the interview, Goulding summarizes PotNetwork’s recent accomplishments and sheds light on how the company has strategized to continue evolving. He also discloses how PotNetwork intends to employ in-house testing on its products in order to facilitate greater discovery of how specific blends can be potentially beneficial to customers. The full interview can be heard at http://cnw.fm/nWn2y. To view the full press release, visit http://cnw.fm/yCA3J…

WednesdayNov 08, 2017 11:05 am

CannabisNewsBreaks – SinglePoint, Inc. (SING) CEO Featured in Uptick Newswire “Stock Day” Interview

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced that CEO Greg Lambrecht was a special guest on the first-ever video recording for Uptick Newswire “Stock Day” with new host Kathryn Donnelly. In the interview, Lambrecht reviews SinglePoint’s plan for bringing revenues in house during 2018, as well as the strategy behind the products that it is marketing to the cannabis sector. Lambrecht concludes the interview by discussing SinglePoint’s efforts to uplist to the OTCQB Venture Market, including outlining how the company will get there and evaluating its current stock price. To review the full interview, visit http://cnw.fm/g8qHN. To…

TuesdayNov 07, 2017 11:20 am

CannabisNewsBreaks – PotNetwork Holding, Inc. (POTN) Strongly Positioned in a Market Projected to Reach $1.8B by 2020

PotNetwork Holding, Inc. (OTC: POTN) is positioned to profit from the continued growth in the cannabidiol (CBD) sector. Boasting an established product line and successful business model, the company and its Diamond CBD subsidiary stand out from competitors. An article discussing this reads: “The hemp-derived cannabidiol (CBD) market is projected to show phenomenal growth over the next few years. The Hemp Business Journal has projected a compound annual growth rate (CAGR) of 53 percent for CBD products derived from hemp, estimating this market to be worth $1.8 billion by 2020 (http://cnw.fm/mu4Ia). PotNetwork Holding, Inc. (OTC: POTN) is in a strong…

MondayNov 06, 2017 12:03 pm

CannabisNewsBreaks – India Globalization Capital (NYSE: IGC) Avoids Regulatory Costs through Cannabis-based Drug Candidates

India Globalization Capital (NYSE AMERICAN: IGC) is developing a portfolio of products using cannabis-based “combination therapies” for the treatment of various life-altering conditions. The company is employing a distinctive strategy to bring these drug candidates to market. An article discussing this reads: “IGC’s unique strategy reduces regulatory approval time and development costs because its chosen categories face lower regulatory burdens. Instead of pursuing full novel drug applications, which take anywhere from 7-9 years in clinical trials and cost hundreds of millions before securing FDA approval, IGC is developing cannabis-based drugs that could be commercialized in less than two years and…

FridayNov 03, 2017 12:16 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Unlocks Ability to Produce 90+ Cannabinoids through Biosynthesis

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues to advance its drug development programs through the use of its proprietary bioinformatics database assessment tool. An article discussing this reads: “InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://cnw.fm/hFe3o). The company recently announced it has enabled the production of all four “gateway” cannabinoids using genetically engineered microorganisms. From these gateway substrates, production of all 90+ cannabinoids is possible via biosynthesis. InMed’s breakthrough stands to make the production of cannabis derivatives, including THC, CBD…

FridayNov 03, 2017 12:15 pm

CannabisNewsBreaks – Skinvisible, Inc.’s (SKVI) Invisicare Technology Tackles Dermatology, CBD Markets

Research and development company Skinvisible, Inc. (OTCQB: SKVI) has developed Invisicare® technology, a patented polymer delivery system that improves the delivery of topically applied skin care products by enhancing the effectiveness of the active ingredients. Skinvisible out-licenses its formulations, enabling companies like Canopy Hemp Corporation to bring their own patented products to market and combat generic competitors. An article discussing this reads: “With a $80 billion global dermatology market and a $30 billion global skin care over-the-counter (OTC) market, the patented polymer delivery system for topical products developed by Skinvisible, obviously, has many, many possible applications. The company has already…

FridayNov 03, 2017 12:14 pm

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Targets Global Cannabis Market

As a licensed producer under the Marijuana for Medical Purposes Regulations in Canada, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) sells cannabis through its ABcann Medicinals, Inc. subsidiary. “We’re now, hopefully, going to be a global presence,” director Aaron Keay said in an interview with CannabisFN (CFN Media). An article discussing this reads: “ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://cnw.fm/3uiqM). The company sells in…

ThursdayNov 02, 2017 2:19 pm

CannabisNewsBreaks – Grey Cloak Tech, Inc. (GRCK) Enters CBD Market through Strategic Acquisition

Grey Cloak Tech, Inc. (OTCQB: GRCK) recently entered the booming cannabis industry through the strategic acquisition of a medically-focused CBD company, Eqova Life Sciences. An article discussing this reads: “On October 24, 2017, Grey Cloak Tech, Inc. (OTCQB: GRCK) announced a 100 percent acquisition of Eqova Life Sciences – a renowned manufacturer of a wide range of hemp oil products. The company sent a letter of intent pertaining to the acquisition in September. Eqova, a company located in Denver, develops clinical-grade full spectrum hemp oil products, and it distributes via partnerships with licensed medical practitioners.” To view the full article,…

ThursdayNov 02, 2017 2:19 pm

CannabisNewsBreaks – India Globalization Capital (NYSE: IGC) Aims to Fast-Track Release of Hyalolex in Recreational Cannabis States

As a first mover in the cannabis-based combination therapy space, India Globalization Capital (NYSE AMERICAN: IGC) is preparing for the launch of its breakthrough treatment aimed at reducing beta-amyloid building up in Alzheimer’s patients, Hyalolex. The classification as a combination therapy enables the company to bring the product to market significantly faster than most pharmaceuticals, because Hyalolex does not need FDA approval. An article discussing this reads: “This hugely accelerated introduction of Hyalolex can only be accomplished in states where medical cannabis is legal and where the ailment (in this case Alzheimer’s) is an approved medical condition. In states where…

News and publishing service for cannabis related companies

Contact us: 303.498.7722

CannabisNewsBreaks